Regulus Therapeutics (RGLS) Shares Down 5.6%

Regulus Therapeutics Inc (NASDAQ:RGLS) shares traded down 5.6% on Tuesday . The stock traded as low as $1.16 and last traded at $1.17. 584,800 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 947,220 shares. The stock had previously closed at $1.24.

Several research analysts recently weighed in on the company. Leerink Swann assumed coverage on Regulus Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price on the stock. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Thursday, January 4th. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $2.46.

The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77. The company has a market cap of $122.67, a PE ratio of -0.88 and a beta of 1.55.

A number of hedge funds and other institutional investors have recently made changes to their positions in RGLS. Quantitative Investment Management LLC acquired a new stake in Regulus Therapeutics in the 2nd quarter valued at $103,000. GSA Capital Partners LLP acquired a new stake in Regulus Therapeutics in the 2nd quarter valued at $139,000. Royal Bank of Canada increased its holdings in Regulus Therapeutics by 12.1% in the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at $347,000. Finally, Goldman Sachs Group Inc. increased its holdings in Regulus Therapeutics by 189.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares in the last quarter. Hedge funds and other institutional investors own 59.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics (RGLS) Shares Down 5.6%” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/01/11/regulus-therapeutics-rgls-shares-down-5-6.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply